Zacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 Million

Wall Street analysts expect Aratana Therapeutics Inc (NASDAQ:PETX) to report $5.72 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Aratana Therapeutics’ earnings. The lowest sales estimate is $2.88 million and the highest is $9.70 million. Aratana Therapeutics reported sales of $290,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 1,872.4%. The firm is expected to report its next quarterly earnings results on Monday, March 12th.

On average, analysts expect that Aratana Therapeutics will report full-year sales of $5.72 million for the current fiscal year, with estimates ranging from $17.99 million to $24.90 million. For the next fiscal year, analysts forecast that the company will report sales of $36.23 million per share, with estimates ranging from $19.28 million to $59.62 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The business had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s revenue was up 1440.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.38) EPS.

A number of analysts have recently commented on PETX shares. Jefferies Group set a $9.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 16th. CL King started coverage on Aratana Therapeutics in a research report on Wednesday, December 27th. They issued a “neutral” rating on the stock. ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Thursday, November 9th. Finally, HC Wainwright started coverage on Aratana Therapeutics in a research report on Friday, November 17th. They issued a “buy” rating and a $10.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $8.55.

In other news, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.70, for a total value of $5,075,941.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the completion of the transaction, the insider now owns 529,359 shares of the company’s stock, valued at $3,705,513. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,057,032 shares of company stock worth $6,186,791. Insiders own 5.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its holdings in Aratana Therapeutics by 0.6% in the 3rd quarter. Janus Henderson Group PLC now owns 1,801,381 shares of the biopharmaceutical company’s stock worth $11,042,000 after acquiring an additional 10,551 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in Aratana Therapeutics by 10.5% in the 3rd quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock worth $5,910,000 after acquiring an additional 91,763 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Aratana Therapeutics by 2.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 388,437 shares of the biopharmaceutical company’s stock worth $2,381,000 after acquiring an additional 7,542 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Aratana Therapeutics by 20.8% in the 3rd quarter. Wells Fargo & Company MN now owns 367,365 shares of the biopharmaceutical company’s stock worth $2,252,000 after acquiring an additional 63,377 shares during the last quarter. Finally, Cadence Capital Management LLC raised its holdings in Aratana Therapeutics by 5.1% in the 3rd quarter. Cadence Capital Management LLC now owns 173,808 shares of the biopharmaceutical company’s stock worth $1,065,000 after acquiring an additional 8,449 shares during the last quarter. Institutional investors own 73.76% of the company’s stock.

Shares of Aratana Therapeutics (PETX) opened at $5.25 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. Aratana Therapeutics has a 12-month low of $4.81 and a 12-month high of $8.34. The company has a market capitalization of $225.75, a P/E ratio of -3.62 and a beta of 3.36.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 Million” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/11/zacks-brokerages-expect-aratana-therapeutics-inc-petx-will-post-quarterly-sales-of-5-72-million.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit